Literature DB >> 22348437

Incidence, risk factors and outcome of histological transformation in follicular lymphoma.

Annarita Conconi1, Carlotta Ponzio, Chiara Lobetti-Bodoni, Maddalena Motta, Paola M V Rancoita, Anastasios Stathis, Alden A Moccia, Luca Mazzucchelli, Francesco Bertoni, Michele Ghielmini, Franco Cavalli, Emanuele Zucca.   

Abstract

Histological transformation (HT) into diffuse large B-cell lymphoma (DLBCL) was documented in 37 of the 281 (13%; 95% CI, 9-18) follicular lymphoma (FL) patients treated at our institute from 1979 to 2007. HT occurred at a median of 2·75 years from initial FL diagnosis and HT rate was 15% at 10 years and 26% at 14 years, with a plateau from that point onward. Patients with bulky or extranodal disease, or those diagnosed before 1990 had a significantly higher risk of HT. When initial treatment strategies were taken into account, a reduced HT risk was seen in the patients initially managed with a 'watch and wait' policy, while the risk appeared significantly increased in the small subset of 18 patients initially managed with rituximab plus chemotherapy (P = 0·0005). HT was associated with a significantly shorter cause-specific survival (P = 0·0002). Predictors of survival after HT were the Follicular Lymphoma International Prognostic Index at diagnosis, as well as age and performance status at the time of HT. Our data confirm the adverse clinical outcome of FL after HT. In keeping with previous isolated reports, our findings suggest that there is a subgroup of patients in whom HT may not occur.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22348437     DOI: 10.1111/j.1365-2141.2012.09054.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  19 in total

1.  Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).

Authors:  Nina D Wagner-Johnston; Brian K Link; Michelle Byrtek; Keith L Dawson; John Hainsworth; Christopher R Flowers; Jonathan W Friedberg; Nancy L Bartlett
Journal:  Blood       Date:  2015-06-23       Impact factor: 22.113

2.  Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.

Authors:  Roopesh Kansara; Joseph M Connors; Kerry J Savage; Alina S Gerrie; David W Scott; Graham W Slack; Randy D Gascoyne; Laurie H Sehn; Diego Villa
Journal:  Haematologica       Date:  2016-06-16       Impact factor: 9.941

3.  Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.

Authors:  C Madsen; M R Clausen; T L Plesner; A Pasanen; T Kuismanen; H H Bentzen; J M Jørgensen; I B Sillesen; B M Himmelstrup; D Rønnov-Jessen; K R Jensen; A M Pettinger; M Ludvigsen; S Leppä; F A d'Amore
Journal:  Blood Adv       Date:  2018-07-10

4.  Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients.

Authors:  Ashish Rai; Loretta J Nastoupil; Jessica N Williams; Joseph Lipscomb; Kevin C Ward; David H Howard; Daniel Lee; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2016-11-10

Review 5.  FDG-PET imaging in hematological malignancies.

Authors:  L Valls; C Badve; S Avril; K Herrmann; P Faulhaber; J O'Donnell; N Avril
Journal:  Blood Rev       Date:  2016-04-16       Impact factor: 8.250

6.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

Authors:  Brian K Link; Matthew J Maurer; Grzegorz S Nowakowski; Stephen M Ansell; William R Macon; Sergei I Syrbu; Susan L Slager; Carrie A Thompson; David J Inwards; Patrick B Johnston; Joseph P Colgan; Thomas E Witzig; Thomas M Habermann; James R Cerhan
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

7.  Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.

Authors:  Jacob P Smeltzer; Jason M Jones; Steven C Ziesmer; Deanna M Grote; Bing Xiu; Kay M Ristow; Zhi Zhang Yang; Grzegorz S Nowakowski; Andrew L Feldman; James R Cerhan; Anne J Novak; Stephen M Ansell
Journal:  Clin Cancer Res       Date:  2014-04-11       Impact factor: 12.531

Review 8.  Transformation in follicular lymphoma: biology, prognosis, and therapeutic options.

Authors:  Eric Wong; Michael Dickinson
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

9.  Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

Authors:  Baldeep Wirk; Timothy S Fenske; Mehdi Hamadani; Mei-Jie Zhang; Zhen-Huan Hu; Görgün Akpek; Mahmoud D Aljurf; Philippe Armand; Ernesto Ayala; Veronika Bachanova; Brian Bolwell; Mitchell S Cairo; Amanda Cashen; Yi-Bin Chen; Luciano J Costa; Shatha Farhan; César O Freytes; James L Gajewski; John Gibson; Gregory A Hale; Leona A Holmberg; Jack W Hsu; David J Inwards; Rummurti T Kamble; Dipnarine Maharaj; Richard T Maziarz; Reinhold Munker; Rajneesh Nath; Nishitha M Reddy; Craig B Reeder; David A Rizzieri; Craig S Sauter; Bipin N Savani; Harry C Schouten; Anna Sureda; Julie M Vose; Edmund K Waller; Peter H Wiernik; Robert Peter Gale; Linda J Burns; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-15       Impact factor: 5.742

10.  Histologically transformed follicular lymphoma exhibits protein profiles different from both non-transformed follicular and de novo diffuse large B-cell lymphoma.

Authors:  M Ludvigsen; C Madsen; P Kamper; S J Hamilton-Dutoit; K Bendix; F d'Amore; B Honoré
Journal:  Blood Cancer J       Date:  2015-03-13       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.